▲ +151.08% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Crinetics Pharmaceuticals in the last 3 months. The average price target is $35.00, with a high forecast of $38.00 and a low forecast of $30.00. The average price target represents a 151.08% upside from the last price of $13.94.
The current consensus among 4 investment analysts is to buy stock in Crinetics Pharmaceuticals.
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly. The company is also developing CRN01941, an oral, selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors; CRN02481, an oral selective nonpeptide somatostatin type 5 receptor agonist used for the treatment of congenital hyperinsulinism; and adrenocorticotrophic hormone antagonist for the treatment of cushing's diseases. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.